Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.

Journal: eLife

Published: 2018-05-01

DOI: 10.7554/elife.32271

Affiliations: 15

Authors: 20

Go to article
Institutions FC
Protein Phosphorylation Laboratory, The Francis Crick Institute, United Kingdom (UK) 0.20
Richard Dimbleby Laboratory of Cancer Research (RDLCR), KCL, United Kingdom (UK) 0.20
Research Complex at Harwell (RCaH), United Kingdom (UK) 0.20
Division of Cancer Studies, KCL, United Kingdom (UK) 0.09
Structural Biology Science Technology Platform (SB STP), The Francis Crick Institute, United Kingdom (UK) 0.05
Department of Biological Regulation, WIS, Israel 0.05
Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK) 0.04
UCL Cancer Institute, United Kingdom (UK) 0.04
Astronomy Centre, University of Sussex, United Kingdom (UK) 0.03
Division of Asthma, Allergy, and Lung Biology, KCL, United Kingdom (UK) 0.03
CRUK/MRC Oxford Institute for Radiation Oncology, United Kingdom (UK) 0.03
Barts Cancer Institute (BCI), QMUL, United Kingdom (UK) 0.03
School of Cancer and Pharmaceutical Sciences, KCL, United Kingdom (UK) 0.03
Breast Cancer Now King's College London Research Unit (BCN-KCL), United Kingdom (UK) 0.01